NPC study maps gene therapy contracting principles

By AI, Created 4:27 PM UTC, May 18, 2026, /AGP/ – A new National Pharmaceutical Council study in JMCP lays out consensus-based steps to make gene therapy payment models more scalable, patient-centered and equitable. The findings highlight data, simplicity and flexibility as key to improving patient access as more therapies reach the market.

Why it matters: - Gene therapies often do not fit traditional reimbursement models because their costs, outcomes and long-term value can be hard to measure upfront. - Better contracting rules could make payment approaches more sustainable and improve equitable access for patients who need these treatments.

What happened: - The National Pharmaceutical Council published new research in the Journal of Managed Care + Specialty Pharmacy on May 14, 2026. - The study, titled “Principles and Practices for Successful Gene Therapy Innovative Contracting: Insights from a Multistakeholder Convening,” developed consensus-based guidance for gene therapy contracting in the U.S. - The work used a mixed-methods approach and brought together payers, manufacturers, employers and patient advocates.

The details: - The research team created two frameworks: one for principles that explain the “why” behind successful contracting and one for practices that describe the “how.” - The study combined a literature review, stakeholder interviews and surveys before and after a virtual convening. - Researchers identified eight principles and seven top-ranked practices that reached stakeholder consensus, defined as at least 75% agreement. - The highlighted priorities include protecting patients from additional out-of-pocket costs, streamlining data collection and reducing complexity. - The study found that stronger data and real-world evidence are needed to address uncertainty around long-term results. - The research also says flexible approaches are needed because each gene therapy has different characteristics. - NPC’s research library includes evidence on the historical landscape of innovative contracts for gene therapies. - The authors say the principles should evolve as new evidence, payment innovation and policy reform emerge.

Between the lines: - The consensus points suggest the field is moving from experimentation toward more standardized contracting rules. - The areas without agreement show where the biggest policy and operational questions remain, especially around patient and provider input, warranty contracts and site-of-care requirements. - The study reinforces a broader shift toward patient-centered evidence generation as gene therapies expand.

What’s next: - As more gene therapies receive FDA approval, stakeholders are likely to keep refining innovative contract designs. - The unresolved issues identified in the study point to more research and dialogue on how to structure these agreements. - Future contracting models will likely need to balance access, evidence collection and administrative burden more carefully.

The bottom line: - The study argues that gene therapy contracting will work best when it is simpler, more flexible and built around better evidence and patient access.